Cohort profile: The themba lethu clinical Cohort, johannesburg, South Africa

International Journal of Epidemiology

Volumn 42, Issue 2, 2013, Pages 430-439

  Fox, Matthew P ^a,b,c   Maskew, Mhairi ^b   Patrick MacPhail, A ^d   Long, Lawrence ^b   Brennan, Alana T ^a,b   Westreich, Daniel ^e   MacLeod, William B ^a,b,c   Majuba, Pappie ^d   Sanne, Ian M ^b,d  

^a BOSTON UNIVERSITY   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d RIGHT TO CARE   (South Africa)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE PLUS LOPINAVIR ZIDOVUDINE; EFAVIRENZ PLUS EMTRICITABINE; EFAVIRENZ PLUS LAMIVUDINE PLUS STAVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS TENOLOVIR; UNCLASSIFIED DRUG;

COHORT ANALYSIS; DATA ACQUISITION; DISEASE TREATMENT; HUMAN IMMUNODEFICIENCY VIRUS; RESEARCH;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ASSESSMENT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOUTH AFRICA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; PRACTICE GUIDELINES AS TOPIC; PROGRAM EVALUATION; SOCIOECONOMIC FACTORS; SOUTH AFRICA; TREATMENT OUTCOME; VIRAL LOAD;

GAUTENG; JOHANNESBURG; SOUTH AFRICA;

EID: 84877041483     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dys029     Document Type: Article

References (44)

1. South Africa National Ministry of Health. National Antiretroviral Treatment Guidelines. 1st edn. Pretoria: Ministry of Health, 2004.
2. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approacy, 2010 Revision. Geneva: WHO, 2010.
3. Department of Health Republic of South Africa. National Strategic Plan for HIV and AIDS/CCMT Monthly Statistics. Pretoria: South African Department of Health, April 2010.
4. WHO, UNICEF. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector. Geneva: World Health Organization, 2010.
5. National Department of Health, Republic of South Africa. Clinical Guidelines for the Management of HIV & AIDS in Adults and Adolescents. Pretoria: South African Department of Health, 2010.
6. Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-26.
7. Severe P, Juste MA, Ambroise A et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363:257-65.
8. Fox MP, Sanne IM, Conradie F et al. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/ml is associated with improved treatment outcomes in South Africa. AIDS 2010;24:2041-50.
9. Sanne IM, Westreich D, Macphail AP, Rubel D, Majuba P, Van Rie A. Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study. J Int AIDS Soc 2009; 12:38.
10. Firnhaber C, Reyneke A, Schulze D et al. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J 2008; 98:541-44.
11. Fox MP, Brennan A, Maskew M, MacPhail P, Sanne I. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health 2010;15:405-13.
12. Fox MP, Ive P, Long L, Maskew M, Sanne I. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010;53:500-06.
13. Larson BA, Brennan A, McNamara L et al. Lost opportunities to complete CD4{thorn} lymphocyte testing among patients who tested positive for HIV in South Africa. Bull World Health Organ 2010;88:675-80.
14. Larson BA, Brennan A, McNamara L et al. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health 2010;15:43-47.
15. Long L, Brennan A, Fox M et al. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med 2011;8:1-10.
16. Long L, Fox M, Sanne I, Rosen S. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010;24:915-19.
17. Rosen S, Ketlhapile M, Sanne I, DeSilva MB. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care 2008;7: 200-07.
18. Rosen S, Ketlhapile M, Sanne I, Desilva MB. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS 2008;22:S131-39.
19. Rosen S, Long L, Fox M, Sanne I. Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa. J Acquir Immune Defic Syndr 2008;48:334.
20. Rosen S, Long L, Sanne I. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health 2008;13: 1005-15.
21. Rosen S, Long L, Sanne I, Stevens WS, Fox MP. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc 2011;14:24.
22. Wallis CL, Mellors JW, Venter WD, Sanne I, Stevens W. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010;53:480-84.
23. Westreich D, Cole SR, Nagar S, Maskew M, van der Horst C, Sanne I. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One 2011;6: e22778.
24. Westreich D, MacPhail P, Van Rie A et al. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS 2009;23:707-15.
25. Westreich DJ, Sanne I, Maskew M et al. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis 2009;48: 1617-23.
26. Brennan A, Evans D, Maskew M et al. Renal dysfunction and the risk of nephrotoxicity and mortality. AIDS 2011; 25:1603-09.
27. Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc 2010;13:49.
28. Brennan A, Long L, Maskew M et al. Outcomes of stable HIV-positive patients down-referred from doctormanaged ART clinics to nurse-managed primary health clinics for monitoring and treatment. AIDS 2011;25: 2027-36.
29. Maskew M, Brennan AT, Macphail AP, Sanne IM, Fox MP. Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care 2011;11:57-65.
30. Malope BI, MacPhail P, Mbisa G et al. No evidence of sexual transmission of Kaposi's sarcoma herpes virus in a heterosexual South African population. AIDS 2008;22: 519-26.
31. Malope BI, Pfeiffer RM, Mbisa G et al. Transmission of Kaposi sarcoma-associated herpesvirus between mothers and children in a South African population. J Acquir Immune Defic Syndr 2007;44:351-55.
32. Malope-Kgokong BI, Macphail P, Mbisa G et al. Kaposi's sarcoma associated-herpes virus (KSHV) seroprevalence in pregnant women in South Africa. Infect Agent Cancer 2010;5:14.
33. Maskew M, MacPhail P, Menezes C, Rubel D. Lost to follow up: contributing factors and challenges in South African patients on antiretroviral therapy. S Afr Med J 2007;97:853-57.
34. Meyer-Rath G, Brennan A, Long L et al. Total cost and potential cost savings of the national antiretroviral treatment (ART) programme in South Africa 2010 to 2017. 18th International AIDS Conference; 2010 July 18-23. Vienna, 2010.
35. Straetemans M, Bierrenbach AL, Nagelkerke N, Glaziou P, van der Werf MJ. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS One 2010;5:e15241.
36. Keiser O, Chi B, Gsponer T et al. Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS 2011;25: 1761-69.
37. Brinkhof MW, Dabis F, Myer L et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008;86:559-67.
38. Brinkhof MW, Egger M, Boulle A et al. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 2007;45:1518-21.
39. Cornell M, Grimsrud A, Fairall L et al. Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 2010;24:2263-70.
40. Egger M, Ekouevi DK, Williams C et al. Cohort Profile: The international epidemiological databases to evaluate AIDS (IeDEA) in sub-Saharan Africa. Int J Epidemiol 2011; doi: 10.1093/ije/dyr080.
41. Fenner L, Forster M, Boulle A et al. Tuberculosis in HIV programmes in lower-income countries: practices and risk factors. Int J Tuberc Lung Dis 2011;15:620-27.
42. Keiser O, Anastos K, Schechter M et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008;13:870-79.
43. Keiser O, Tweya H, Boulle A et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009;23:1867-74.
44. Keiser O, Tweya H, Braitstein P et al. Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010;15:251-58.